Clinical Trial Update: A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) [Phase 2]

View source ↗

Summary

Phase 2 trial of MK-8998 in acutely psychotic participants with schizophrenia has completed, and results were posted in 2014. Sponsor: Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MK-8998

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2014-02-06